莱斯康制药宣布，其针对糖尿病周围神经病变性疼痛的候选药物Pilavapadin，已顺利完成与美国食品药品监督管理局（FDA）的二期临床试验末次会议。此次会议标志着该药物研发进程中的重要里程碑，为后续临床研究计划的推进奠定了坚实基础。
莱斯康制药宣布，其针对糖尿病周围神经病变性疼痛的候选药物Pilavapadin，已顺利完成与美国食品药品监督管理局（FDA）的二期临床试验末次会议。此次会议标志着该药物研发进程中的重要里程碑，为后续临床研究计划的推进奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.